Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma.

MLA

Krishnan, Amrita, et al. “Teclistamab versus Real-World Physician’s Choice of Therapy in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.” Journal of Comparative Effectiveness Research, vol. 12, no. 6, June 2023, p. e220186. EBSCOhost, https://doi.org/10.57264/cer-2022-0186.

APA

Krishnan, A., Nooka, A. K., Chari, A., Garfall, A. L., Martin, T. G., Nair, S., Lin, X., Qi, K., Londhe, A., Pei, L., Ammann, E., Kobos, R., Smit, J., Parekh, T., Marshall, A., Slavcev, M., & Usmani, S. Z. (2023). Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma. Journal of Comparative Effectiveness Research, 12(6), e220186. https://doi.org/10.57264/cer-2022-0186

Chicago

Krishnan, Amrita, Ajay K Nooka, Ajai Chari, Alfred L Garfall, Thomas G Martin, Sandhya Nair, Xiwu Lin, et al. 2023. “Teclistamab versus Real-World Physician’s Choice of Therapy in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.” Journal of Comparative Effectiveness Research 12 (6): e220186. doi:10.57264/cer-2022-0186.